Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18660591 | ANTI-SIRPalpha ANTIBODY | May 2024 | July 2025 | Allow | 15 | 0 | 0 | Yes | No |
| 18426912 | FUSION PROTEIN AND NUCLEIC ACID ENCODING SEQUENCE THEREOF, AND USES OF THE SAME | January 2024 | November 2024 | Allow | 10 | 2 | 0 | Yes | No |
| 18420296 | ANTI-NGF ANTIBODIES AND USES THEREOF | January 2024 | March 2025 | Allow | 14 | 2 | 1 | Yes | No |
| 18348173 | ANTI-NGF ANTIBODIES AND USES THEREOF | July 2023 | May 2024 | Allow | 10 | 1 | 1 | No | No |
| 18206552 | T CELL REGULATION | June 2023 | March 2025 | Abandon | 21 | 0 | 1 | No | No |
| 18125400 | METHODS FOR TREATING AND DIAGNOSING SYSTEMIC LUPUS ERYTHEMATOSUS BY MEASURING LEVELS OF BIOMARKERS, SUCH AS ERYTHROCYTE-BOUND C4D, B-LYMPHOCYTE-BOUND C4D, ANTI-SJOGREN'S SYNDROME TYPE B ANTIGEN, SCL-70 ANTIBODY, JO-1 ANTIBODY, AND ANTI-CENTROMERE PROTEIN B, IN SUBJECTS; IDENTIFYING SUBJECTS AS HAVING SYSTEMIC LUPUS ERYTHEMATOSUS BASED ON BIOMARKER LEVELS; AND TREATING SUBJECTS FOR SYSTEMIC LUPUS ERYTHEMATOSUS | March 2023 | August 2025 | Abandon | 29 | 3 | 1 | Yes | Yes |
| 18178278 | ANTI-PD1 ANTIBODIES AND METHODS OF USE | March 2023 | November 2025 | Abandon | 33 | 1 | 0 | No | No |
| 18152078 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES | January 2023 | November 2025 | Abandon | 34 | 1 | 0 | No | No |
| 18012580 | ANTIBODIES SPECIFICALLY RECOGNIZING C5A AND USES THEREOF | December 2022 | November 2025 | Allow | 35 | 0 | 1 | Yes | No |
| 17996866 | IMPROVED PEPTIDE VACCINE | October 2022 | February 2026 | Abandon | 40 | 1 | 0 | No | No |
| 17821706 | Nanobody Target GCC and Uses in Chimeric Antigen Receptor Cell Therapy | August 2022 | December 2023 | Allow | 16 | 0 | 1 | Yes | No |
| 17891020 | Compositions and Methods for Treatment and Prevention of Type 1 Diabetes | August 2022 | May 2024 | Abandon | 21 | 1 | 0 | No | No |
| 17818072 | CLDN18.2-TARGETING ANTIBODY, BISPECIFIC ANTIBODY AND USE THEREOF | August 2022 | April 2025 | Allow | 32 | 2 | 1 | No | No |
| 17817448 | ANTI-CD47 ANTIBODY AND USES THEREOF | August 2022 | September 2023 | Allow | 13 | 0 | 0 | Yes | No |
| 17854211 | TREATMENTS FOR DIFFUSE LARGE B-CELL LYMPHOMA | June 2022 | April 2024 | Abandon | 22 | 1 | 0 | No | No |
| 17778689 | METHODS OF CANCER TREATMENT USING ANTI-OX40 ANTIBODIES IN COMBINATION WITH ANTI-TIM3 ANTIBODIES | May 2022 | December 2025 | Abandon | 43 | 1 | 0 | No | No |
| 17767695 | T CELL RECEPTOR RECOGNISING KRAS MUTATION AND ENCODING SEQUENCE THEREOF | April 2022 | January 2026 | Allow | 45 | 2 | 0 | No | No |
| 17642340 | USE OF HIGH-AFFINITY, LIGAND-BLOCKING, HUMANIZED ANTI-T-CELL IMMUNOGLOBULIN DOMAIN AND MUCIN DOMAIN-3 (TIM-3) IGG4 ANTIBODY FOR THE TREATMENT OF MYELOFIBROSIS | March 2022 | November 2025 | Abandon | 44 | 1 | 0 | No | No |
| 17572611 | USE OF CD8-TARGETED VIRAL VECTORS | January 2022 | August 2025 | Abandon | 43 | 2 | 1 | No | No |
| 17541273 | STABILIZED ARTIFICIAL IMMUNE COMPLEX ACTIVE IMMUNIZATION STRATEGY THAT SUPPORTS B CELL AND DENDRITIC CELL PROGRAMMING FOR CANCER IMMUNOTHERAPY | December 2021 | July 2024 | Abandon | 31 | 1 | 0 | No | No |
| 17616043 | Bispecific Antibody, Preparation Method Therefor and Application Thereof | December 2021 | November 2025 | Allow | 48 | 2 | 0 | Yes | No |
| 17615555 | ENGINEERING THE HINGE REGION TO DRIVE ANTIBODY DIMERIZATION | November 2021 | December 2025 | Allow | 49 | 1 | 1 | No | No |
| 17607807 | BISPECIFIC ANTIBODY WITH DOUBLE HER2 SITES FOR TUMOR IMMUNOTHERAPY | October 2021 | October 2025 | Abandon | 48 | 1 | 0 | No | No |
| 17606744 | BISPECIFIC ANTIBODIES AGAINST PD-1 AND LAG-3 | October 2021 | September 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17489598 | MODULATORS OF CELL SURFACE PROTEIN INTERACTIONS AND METHODS AND COMPOSITIONS RELATED TO SAME | September 2021 | May 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17599716 | ANTI-INTEGRIN ANTIBODIES AND USES THEREOF | September 2021 | February 2026 | Abandon | 52 | 1 | 1 | No | No |
| 17442638 | MONOCLONAL ANTIBODY AGAINST STIM1 | September 2021 | July 2025 | Allow | 46 | 1 | 1 | Yes | No |
| 17425125 | NOVEL BISPECIFIC ANTIBODY MOLECULE AND BISPECIFIC ANTIBODY SIMULTANEOUSLY BINDING TO PD-L1 AND LAG-3 | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17425022 | CD31 COMPETITORS AND USES THEREOF | July 2021 | February 2025 | Abandon | 43 | 0 | 1 | No | No |
| 17413696 | ANTIBODIES THAT NEUTRALIZE HEPATITIS B VIRUS AND USES THEREOF | June 2021 | December 2024 | Allow | 42 | 1 | 0 | Yes | No |
| 17413269 | ANTI-IL-27 ANTIBODIES AND USES THEREOF | June 2021 | March 2025 | Allow | 45 | 1 | 1 | Yes | No |
| 17312630 | NOVEL POLYPEPTIDES | June 2021 | April 2025 | Abandon | 46 | 1 | 1 | No | No |
| 17312847 | ANTI-TIM-3 ANTIBODIES AND USES THEREOF | June 2021 | March 2025 | Abandon | 45 | 1 | 0 | No | No |
| 17312522 | NOVEL POLYPEPTIDES | June 2021 | January 2026 | Allow | 55 | 2 | 1 | Yes | No |
| 17341201 | BORRELIA BURGDORFERI PEPTIDOGLYCAN AS A DIAGNOSTIC AND TARGET FOR THERAPEUTIC INTERVENTION OF LYME DISEASE-RELATED PATHOLOGIES | June 2021 | September 2025 | Allow | 52 | 2 | 1 | Yes | No |
| 17298381 | FULLY HUMANIZED ANTI-GITR ANTIBODY AND PREPARATION METHOD THEREFOR | May 2021 | November 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17297421 | ANTIBODIES SPECIFICALLY RECOGNIZING GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR ALPHA AND USES THEREOF | May 2021 | July 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17297386 | HUMANIZED ANTI-HUMAN OX40 MONOCLONAL ANTIBODY, PREPARATION METHOD THEREFOR AND USE THEREOF | May 2021 | November 2024 | Allow | 41 | 1 | 0 | Yes | No |
| 17297333 | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY | May 2021 | August 2024 | Abandon | 39 | 0 | 1 | No | No |
| 17296072 | METHODS AND COMPOSITIONS FOR TREATING CANCER | May 2021 | July 2025 | Allow | 50 | 2 | 2 | No | No |
| 17314987 | TREATMENT METHOD FOR PSORIASIS | May 2021 | February 2025 | Abandon | 46 | 1 | 0 | No | No |
| 17290501 | Monoclonal Antibodies to ELTD1 and Uses Thereof | April 2021 | August 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17287643 | NY-ESO-1 T CELL RECEPTORS AND METHODS OF USE THEREOF | April 2021 | July 2025 | Allow | 51 | 2 | 1 | Yes | No |
| 17218752 | BISPECIFIC ANTIGEN BINDING MOLECULES WITH TRIVALENT BINDING TO CD40 | March 2021 | August 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17278509 | INTRABODIES FOR REDUCING FUT8 ACTIVITY | March 2021 | December 2024 | Allow | 45 | 1 | 1 | No | No |
| 17202004 | METHODS AND MATERIALS FOR MODULATING AN IMMUNE RESPONSE | March 2021 | December 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17273538 | MONOCLONAL ANTIBODIES AGAINST ENDOTROPHIN AND THE USE THEREOF | March 2021 | February 2025 | Allow | 47 | 2 | 1 | Yes | No |
| 17186704 | MATERIALS AND METHODS FOR MODULATING AN IMMUNE RESPONSE | February 2021 | November 2025 | Allow | 57 | 3 | 1 | Yes | No |
| 17270947 | ANTI-CD47 ANTIBODY AND APPLICATION THEREOF | February 2021 | March 2024 | Allow | 36 | 0 | 0 | Yes | No |
| 17269315 | ANTAGONISTIC ANTI-TUMOR NECROSIS FACTOR RECEPTOR SUPERFAMILY POLYPEPTIDES | February 2021 | January 2026 | Allow | 59 | 2 | 1 | No | No |
| 17176427 | TREATMENT OF TRIPLE NEGATIVE BREAST CANCER WITH TARGETED TGF-B INHIBITION | February 2021 | June 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17175086 | ANTI-INTERFERON GAMMA ANTIBODIES AND USES THEREOF | February 2021 | April 2025 | Allow | 50 | 2 | 1 | Yes | No |
| 17174231 | ENGINEERED BISPECIFIC PROTEINS | February 2021 | August 2024 | Abandon | 42 | 1 | 1 | No | No |
| 17266966 | PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | February 2021 | January 2025 | Allow | 47 | 2 | 0 | Yes | Yes |
| 17266092 | ANTI-SIGLEC ANTIBODY, PHARMACEUTICAL COMPOSITION COMPRISING THE SAME, AND USES THEREOF | February 2021 | June 2024 | Allow | 40 | 1 | 0 | No | No |
| 17265879 | PROTEINS BINDING NKG2D, CD16 AND A TUMOR-ASSOCIATED ANTIGEN | February 2021 | June 2025 | Abandon | 52 | 2 | 1 | No | No |
| 17265095 | ANTI-ROR1 MONOCLONAL ANTIBODY, FUNCTIONAL FRAGMENT THEREOF, GENE, DRUG DELIVERY COMPOSITION, AND PHARMACEUTICAL COMPOSITION | February 2021 | August 2024 | Abandon | 43 | 1 | 0 | No | No |
| 17264972 | MUSCLE TARGETING COMPLEXES AND USES THEREOF FOR TREATING HYPERTROPHIC CARDIOMYOPATHY | February 2021 | January 2024 | Abandon | 36 | 1 | 0 | No | No |
| 17164334 | MARROW INFILTRATING LYMPHOCYTES (MILs) EXPRESSING CHIMERIC ANTIGEN RECEPTORS (CAR), METHOD OF MANUFACTURING SAME, AND METHOD OF USING IN THERAPY | February 2021 | July 2024 | Abandon | 41 | 0 | 1 | No | No |
| 17265143 | ANTIBODY BINDING TO HUMAN HER2 AND PREPARATION METHOD AND USE THEREOF | February 2021 | January 2025 | Allow | 48 | 1 | 0 | Yes | No |
| 17262629 | Composition for Preventing or Treating Immune-Related Diseases | January 2021 | September 2024 | Abandon | 44 | 1 | 0 | No | No |
| 17261488 | ANTI-LYPD3 CAR T-CELL THERAPY FOR THE TREATMENT OF CANCER | January 2021 | October 2024 | Abandon | 45 | 1 | 1 | No | No |
| 17260977 | CHIMERIC RECEPTORS TO STEAP1 AND METHODS OF USE THEREOF | January 2021 | October 2025 | Abandon | 57 | 3 | 1 | No | No |
| 17259868 | BCMA-TARGETING CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | January 2021 | February 2025 | Abandon | 49 | 1 | 0 | No | No |
| 17259791 | ANTIBODY MOLECULES THAT BIND PD-L1 AND CD137 | January 2021 | September 2024 | Allow | 44 | 1 | 1 | Yes | No |
| 17259816 | ANTI-GPC3 SINGLE-CHAIN ANTIBODY-CONTAINING CAR | January 2021 | December 2024 | Abandon | 47 | 2 | 0 | No | No |
| 17259303 | METHODS FOR DETECTING AND TREATING CANCERS HAVING ADENOSINE PATHWAY ACTIVATION | January 2021 | June 2024 | Allow | 41 | 2 | 0 | No | No |
| 17258115 | ANTI-SIRPalpha ANTIBODY | January 2021 | February 2024 | Allow | 38 | 0 | 1 | Yes | No |
| 17254479 | ZIKA NEUTRALIZING ANTIBODY COMPOSITIONS AND METHODS OF USING THE SAME | December 2020 | May 2024 | Abandon | 41 | 1 | 0 | No | No |
| 17253501 | BISPECIFIC ANTIBODIES | December 2020 | April 2024 | Abandon | 40 | 0 | 1 | No | No |
| 17253487 | ANTI-MESOTHELIN CONSTRUCTS AND USES THEREOF | December 2020 | May 2024 | Allow | 40 | 1 | 1 | No | No |
| 17252329 | LIGANDS TO LIGHT OR ITS RECEPTOR LTßR FOR USE IN HAEMATOLOGIC MALIGNANCIES | December 2020 | June 2025 | Allow | 54 | 3 | 0 | No | No |
| 16973125 | METHODS AND COMPOSITIONS RELATING TO HIGH-THROUGHPUT MODELS FOR ANTIBODY DISCOVERY AND/OR OPTIMIZATION | December 2020 | April 2024 | Abandon | 40 | 1 | 0 | No | No |
| 17250053 | CHIMERIC ANTIGEN RECEPTOR | November 2020 | September 2024 | Allow | 46 | 1 | 1 | Yes | No |
| 17054217 | Eosinophil Cationic Protein (ECP) as a Tumor Marker for Malignant Tumors | November 2020 | May 2024 | Abandon | 42 | 1 | 0 | No | No |
| 16770193 | NEW DRUG SCREENING ASSAY USING REGULATORY MACROPHAGES | June 2020 | December 2024 | Abandon | 54 | 1 | 1 | No | No |
| 16622901 | METHODS AND KITS FOR EVALUATING CLINICAL OUTCOMES OF AUTOIMMUNE DISEASE | December 2019 | May 2025 | Allow | 60 | 3 | 1 | Yes | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner SWARTWOUT, BRIANNA KENDALL.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 0.0% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is in the bottom 25% across the USPTO, indicating that filing appeals is less effective here than in most other areas.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner SWARTWOUT, BRIANNA KENDALL works in Art Unit 1644 and has examined 58 patent applications in our dataset. With an allowance rate of 48.3%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 45 months.
Examiner SWARTWOUT, BRIANNA KENDALL's allowance rate of 48.3% places them in the 11% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by SWARTWOUT, BRIANNA KENDALL receive 1.21 office actions before reaching final disposition. This places the examiner in the 15% percentile for office actions issued. This examiner issues significantly fewer office actions than most examiners.
The median time to disposition (half-life) for applications examined by SWARTWOUT, BRIANNA KENDALL is 45 months. This places the examiner in the 12% percentile for prosecution speed. Applications take longer to reach final disposition with this examiner compared to most others.
Conducting an examiner interview provides a +78.9% benefit to allowance rate for applications examined by SWARTWOUT, BRIANNA KENDALL. This interview benefit is in the 99% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.
When applicants file an RCE with this examiner, 46.4% of applications are subsequently allowed. This success rate is in the 96% percentile among all examiners. Strategic Insight: RCEs are highly effective with this examiner compared to others. If you receive a final rejection, filing an RCE with substantive amendments or arguments has a strong likelihood of success.
This examiner enters after-final amendments leading to allowance in 50.0% of cases where such amendments are filed. This entry rate is in the 74% percentile among all examiners. Strategic Recommendation: This examiner shows above-average receptiveness to after-final amendments. If your amendments clearly overcome the rejections and do not raise new issues, consider filing after-final amendments before resorting to an RCE.
This examiner withdraws rejections or reopens prosecution in 100.0% of appeals filed. This is in the 87% percentile among all examiners. Of these withdrawals, 100.0% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.
When applicants file petitions regarding this examiner's actions, 66.7% are granted (fully or in part). This grant rate is in the 71% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 0.0% of allowed cases (in the 2% percentile). This examiner rarely makes examiner's amendments compared to other examiners. You should expect to make all necessary claim amendments yourself through formal amendment practice.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 7.1% of allowed cases (in the 85% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.